SEMINAR: The discovery of a novel cancer target and clinical development of targeted therapy with leronlimab
|The discovery of a novel cancer target and clinical development of targeted therapy with leronlimab
Richard Pestell graduated MBBS from the University of WA, gained fellowships in endocrinology and oncology with RACP
and completed PhD at the University of Melbourne (Howard Florey Institute) before postdoctoral research at Harvard Medical School. He has directed broadly collaborating laboratories, producing highly cited research on signaling in endocrine cancer oncogenesis and metastasis. Most recently, this has included exploring the CCR5 receptor as a novel therapeutic target for the humanized anti-CCR5 antibody, leronlimab. Richard has allied active research with clinical and research administration, as director of Philadelphia’s Sydney Kimmel Cancer Center and Executive Vice President of Thomas Jefferson University until 2015 and currently as President of the Pennsylvania Cancer and Regenerative Medicine Center, also in Philadelphia. He is the holder of a number of international patents in biotechnology, diagnostics and cancer therapeutics, has established two successful biotech companies.
- Locations of venues on the Crawley and Nedlands campuses are
available via the Campus Maps website.
- Download this event as:
Mail this event: